Stock UCBUCB
Add to a list
To use this feature you must be a member
Log inSign up

UCB Stock

Equities

UCB

BE0003739530

Pharmaceuticals

Market Closed - Euronext Bruxelles
Other stock markets
 12:35:30 2025-03-17 pm EDT 		5-day change 1st Jan Change
184.95 EUR +2.84% Intraday chart for UCB +9.18% -3.77%
Mar. 12 Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of Fintepla (Fenfluramine) in Children and Adults with Dravet Syndrome CI
Mar. 10 Saniona Names New Chief Medical Officer MT

Valuation: UCB

Capitalization 35.15B 38.38B 33.8B 29.55B 54.83B 3,327B 60.17B 387B 147B 1,406B 144B 141B 5,702B P/E ratio 2025 *
34.1x
P/E ratio 2026 * 23.8x
Enterprise value 35.62B 38.9B 34.26B 29.95B 55.58B 3,372B 60.98B 392B 149B 1,425B 146B 143B 5,779B EV / Sales 2025 *
5.23x
EV / Sales 2026 * 4.41x
Free-Float
61.3%
Yield 2025 *
0.79%
Yield 2026 * 0.81%
More valuation ratios * Estimated data

Chart: UCB

Dynamic Chart

Latest news: UCB

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of Fintepla (Fenfluramine) in Children and Adults with Dravet Syndrome Mar. 12 CI
Saniona Names New Chief Medical Officer Mar. 10 MT
Bimzelx Two-Year Data At AAD Showed Potential To Eliminate Draining Tunnels In Hidradenitis Suppurativa Mar. 07 RE
UCB SA Announces Bimzelx® (Bimekizumab-Bkzx) Two-Year Data At Aad Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden Mar. 07 CI
AlphaValue/Baader Europe Notes UCB's Lower-than-Expected Outlook After Strong H2 2024 Performance Mar. 03 MT
UCB : Lower-than-expected 2025 guidance weighed on good H2 24 results Feb. 28Alphavalue
UCB SA, 2024 Earnings Call, Feb 27, 2025 Feb. 27
UCB SA Provides Earnings Guidance for the 2025 Feb. 27 CI
UCB SA Reports Earnings Results for the Full Year Ended December 31, 2024 Feb. 26 CI
UCB?s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market Feb. 13 CI
UCB's BIMZELX Demonstrates Sustained Disease Control In Hidradenitis Suppurativa Feb. 12 RE
UCB Invests Over EUR 100 Mln In Construction Of New R&D Centre Feb. 10 RE
UCB SA Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 Jan. 14
More news

Last Transcript: UCB

Logo UCB
UCB SA, 2024 Earnings Call, Feb 27, 2025
Feb. 27
More transcripts

Analysts' recommendations: UCB

UCB : Lower-than-expected 2025 guidance weighed on good H2 24 results Feb. 28Alphavalue
UCB : Oddo BHF raises its target price Dec. 02 CF
UCB: further rebound, Jefferies remains Buy Nov. 06 CF
UCB : Jefferies raises its target price Nov. 06 CF
UCB : Too hot to handle, despite expectations being revised higher 24-10-09Alphavalue
More recommendations

Press Releases: UCB

UCB : Acquisition of own shares Mar. 14 PU
UCB : Transparency notification BlackRock, Inc. Mar. 11 PU
Share Repurchase Program 2025 to cover UCB's Long Term Incentive Plans for employees Mar. 10 AQ
UCB : Share Repurchase Program 2025 to cover UCB's Long Term Incentive Plans for employees Mar. 07 PU
UCB : Collaboration and innovation drives RealiseD Project to Change the Paradigm for Clinical Trials in Rare and Ultra-Rare Diseases Feb. 28 PU
More press releases

News in other languages: UCB

Farma en D'Ieteren vallen op in Brussel Mar. 15
UBS verhoogt koersdoel Argenx naar 620 dollar Mar. 12
UCB presenteert meerderjarige studieresultaten bij gebruik Bimzelx Mar. 07
Trump vole la vedette à Nvidia Feb. 27
En direct des marchés : AXA, Veolia, Engie, Vusiongroup… avalanche de publications ! Feb. 27
More news

Quotes and Performance

1 day+2.84%
1 week+9.18%
Current month+1.87%
1 month+1.48%
3 months-0.51%
6 months+16.43%
Current year-3.77%
More quotes

Course Extremes

1 week
169.6
Extreme 169.6
184.95
1 month
166.5
Extreme 166.5
196.85
Current year
166.5
Extreme 166.5
198.95
1 year
107.3
Extreme 107.3
198.95
3 years
65.4
Extreme 65.4
198.95
5 years
60.18
Extreme 60.18
198.95
10 years
54.84
Extreme 54.84
198.95
More quotes

Managers and Directors: UCB

Manager TitleAgeSince
Jean-Christophe Tellier CEO
 Chief Executive Officer 66 2014-12-31
Sandrine Dufour DFI
 Director of Finance/CFO 58 2020-06-30
Kirsten Lund Jurgensen CTO
 Chief Tech/Sci/R&D Officer 66 2018-12-31
Director TitleAgeSince
Charles-Antoine Janssen BRD
 Director/Board Member 54 2011-12-31
Jean-Christophe Tellier BRD
 Director/Board Member 66 2014-12-31
Jonkheer Cédric van Rijckevorsel BRD
 Director/Board Member 55 2014-04-23
More insiders

Biopharmaceuticals

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
UCB Stock UCB
+2.84%+9.18%+77.16%+78.35% 37.18B
CSL LIMITED Stock CSL Limited
+0.63%-1.00%-10.79%-7.95% 76.47B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.71%+6.90%+29.42%+31.17% 51.52B
BIOGEN INC. Stock Biogen Inc.
+2.94%-4.76%-34.55%-30.09% 20.41B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+12.12%+18.15%+114.91%+766.01% 14.39B
INTRA-CELLULAR THERAPIES, INC. Stock Intra-Cellular Therapies, Inc.
+0.14%+0.15%+102.92%+117.70% 13.96B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
+3.04%-0.67%-14.69%-10.87% 13.25B
INCYTE CORPORATION Stock Incyte Corporation
-8.62%-12.82%+6.24%-16.60% 13.13B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-2.42%+0.37%-5.94%-47.35% 12.01B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
-1.71%-3.37%+5.83%+42.22% 9.89B
Average +1.07%+0.51%+27.05%+92.26% 26.22B
Weighted average by Cap. +1.37%+0.18%+22.19%+58.92%
See all sector performances

Financials

2025 *2026 *
Net sales 6.82B 7.44B 6.56B 5.73B 10.63B 645B 11.67B 75.06B 28.51B 273B 27.89B 27.33B 1,106B 7.78B 8.49B 7.48B 6.54B 12.14B 736B 13.32B 85.67B 32.54B 311B 31.84B 31.2B 1,262B
Net income 1.02B 1.12B 984M 861M 1.6B 96.89B 1.75B 11.27B 4.28B 40.94B 4.19B 4.1B 166B 1.45B 1.58B 1.39B 1.22B 2.26B 137B 2.48B 15.93B 6.05B 57.85B 5.92B 5.8B 235B
Net Debt 476M 520M 458M 400M 742M 45.05B 815M 5.24B 1.99B 19.03B 1.95B 1.91B 77.2B -874M -954M -840M -735M -1.36B -82.71B -1.5B -9.62B -3.66B -34.95B -3.58B -3.5B -142B
More financial data * Estimated data

Company Profile

Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,215
Sector
Pharmaceuticals
Calendar
Jul. 23 - Q2 2025 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
25-03-17 184.95 € +2.84% 233,495
25-03-14 179.85 € -0.42% 187,240
25-03-13 180.60 € -0.22% 327,916
25-03-12 181.00 € +6.88% 487,575
25-03-11 169.35 € -0.03% 373,235

Real-time Euronext Bruxelles, March 17, 2025 at 12:35 pm EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG MSCI
AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
184.95EUR
Average target price
211.61EUR
Spread / Average Target
+14.42%
Consensus
Profit revisions
Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. UCB Stock